Trial Profile
A phase II evaluation of oral enzastaurin HCl in second- and third-line treatment of patients with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2007
Price :
$35
*
At a glance
- Drugs Enzastaurin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Jun 2007 Interim results reported at ASCO 2007.
- 09 Sep 2005 New trial record.